Valneva : A new phase II in Lyme disease which confirms our opinion
>Another positive phase II result in Lyme disease - Valneva launched second phase II testing on its candidate vaccine for Lyme disease after the first positive results from VLA15-201. This second confirmatory study evaluated the new vaccination regimen, which is longer at 0, 2 and 6 months with an identical dose as the first study at 135 µg and 180 µg. The results were positive once again. Whether in terms of efficacy or safety, the candidate vaccine met the new ...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.